✦ LIBER ✦

Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)

✍ Scribed by Petruzelka, Lubos

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PD-151 Mutations in the epidermal growth

✍ Nederlof, P.; Boerrigter, L.; van 't Veer, L.; Baas, P.; van Zandwijk, N. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 261 KB

PCN17 Indirect Comparison of the Efficac

✍ C. Pereira; M. Sanches; J.F. Loff 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Gefitinib as first-line treatment for pa

✍ Gridelli, C.; De Marinis, F.; Di Maio, M.; Cortinovis, D.; Cappuzzo, F.; Mok, T. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 216 KB

PCN82 Cost-Effectiveness Analysis of Erl

✍ P. Garrido; G. López-Vivanco; R. Rosell; B. Espinós; A. Castro-Gomez 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (

✍ G. de Lima Lopes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Epidermal growth factor receptor (EGFR)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB